Adsorbed diphtheria tetanus acellular pertussis combined vaccine - Changchun BCHT Biotechnology
Alternative Names: Acellular DPT (three-component) combined vaccine - Changchun BCHT Biotechnology; DTaP vaccine - Changchun BCHT BiotechnologyLatest Information Update: 02 Feb 2022
At a glance
- Originator Changchun BCHT Biotechnology
- Class Antibacterials; Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Diphtheria; Pertussis; Tetanus
Most Recent Events
- 10 Dec 2021 Phase-I/II clinical trials in Diphtheria (In children, In infants, Prevention) in China (Parenteral) (NCT05189548)
- 10 Dec 2021 Phase-I/II clinical trials in Pertussis (In children, In infants, Prevention) in China (Parenteral) (NCT05189548)
- 10 Dec 2021 Phase-I/II clinical trials in Tetanus (In children, In infants, Prevention) in China (Parenteral) (NCT05189548)